menu ☰
menu ˟

VEGF inhibitors may augment immunotherapy efficacy for first-line renal cell carcinoma

04 Nov 2017
MIAMI — Vascular endothelial growth factor inhibitors may augment the efficacy observed with immuno-oncology agents for first-line treatment of renal cell carcinoma, according to a presenter at International Kidney Cancer Symposium.“PD-1-expressi...

Click here to view the full article which appeared in Hematology Oncology

IPH Logo